Artiva Biotherapeutics, Inc. Net Fee Amt
Artiva Biotherapeutics, Inc. (ARTV) had Net Fee Amt of $7.50 thousand as of 2026-09-11, per its S-8 filed 2026-09-11.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-09-11
- 2026-09-11: Net Fee Amt $7.50K.
- 2026-08-04: Net Fee Amt $55.24K.
| Period end | Net Fee Amt |
|---|---|
| 2026-09-11 | $7.50K S-8 · filed 2026-09-11 |
| 2026-08-04 | $55.24K S-3 · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |